

# ACC HIGHLIGHTS

2026

ON DEMAND

Developed by:



## Program Overview:

This program will cover the key clinical trial findings and their implications from ACC 2026. This program is intended for cardiovascular specialists and primary care physicians.

## Discussion Topics:

- **CHAMPION-AF:** How does left atrial appendage occlusion compare to anticoagulation in AF?
- **SCOUT-HCM:** Extending the benefits of mavacamten to adolescents with obstructive hypertrophic cardiomyopathy.
- **CORALreef Add-On:** How does an oral PCSK9 inhibitor compare to ezetimibe, bempedoic acid, or their combination?
- **Ez-PAVE:** Is achieving a target LDL-C of <1.4 superior to <1.8 in patients with ASCVD?
- **VESALIUS:** Does evolocumab reduce events in patients with diabetes but without known atherosclerosis?

## Learning Objectives:

- Review trials and data presented at ACC 2026
- Examine where the data presented may impact clinical practice guidelines
- Apply the latest evidence-based strategies in clinical practice



View OnDemand  
[www.ccrnmd.com/webcasts](http://www.ccrnmd.com/webcasts)

## SPEAKERS



### Milan Gupta

MD, FRCPC, FCCS, CPC(HC)

Assistant Professor,  
Department of Medicine,  
University of Toronto  
Medical Director,  
Collaborative CME and Research Network  
Brampton, ON



### Narendra Singh

MD, FRCPC, FCCS, FACC, FAHA

Director,  
NSC Cardiology  
Clinical Assistant Professor,  
Medical College of Georgia at  
Augusta University & Mercer University  
Atlanta, GA

This program was developed by CCRN and has received unrestricted educational grants from BMS and Merck.

